Trevi Therapeutics reports FY2023 net loss $29.1M; cash $83M; trial timelines reaffirmed

Trevi Therapeutics, Inc.

Net loss Q4 2023 $7.8M vs $5.5M in Q4 2022; FY2023 net loss $29.1M vs $29.2M in FY2022.
Cash, cash equivalents and marketable securities $83.0M at year-end 2023; expected runway into 2026.
Phase 2a RIVER trial for RCC topline data expected H2 2024; enrollment continuing across multiple sites.
Phase 2b CORAL trial for chronic cough in IPF topline expected H1 2025; SSRE expected H2 2024.
Human Abuse Potential study over 50% enrolled; topline data expected H2 2024.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Trevi Therapeutics, Inc. reported quarter and year ended December 31, 2023 results: net income Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.. Guidance reaffirmed.

Period: quarter and year ended December 31, 2023
Net income: Net loss: For the fourth quarter of 2023, the Company reported a net loss of $7.8 million, compared to a net loss of $5.
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Trevi Therapeutics, Inc., a Delaware corporation (the “Company”) announced its financial results for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Trevi Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-034159

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.